Benjamín Gómez-Navarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Benjamín Gómez-Navarro has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Bravo-Acevedo
Blood Bank, UMAE Hospital de Gineco Obstetricia No. 4 "Luis Castelazo Ayala", Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico
5 shared publications Araceli Escobedo-Ruíz
Histocompatibility Laboratory, Specialty Hospital, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico
5 shared publications- Carolina Bekker-Méndez
Unidad de Investigación Biomédica en Inmunología e Infectología, Hospital de Infectología “Dr. Daniel Méndez Hernández”, Centro Médico Nacional “La Raza”, Instituto Mexicano del Seguro Social (IMSS), Mexico City 02990, Mexico
5 shared publications - Diana Iraíz Hernández-Zaragoza
Molecular Genetics Laboratory, Escuela Nacional de Antropología e Historia (ENAH), Mexico City, Mexico; Immunogenetics Unit, Técnicas Genéticas Aplicadas a la Clínica (TGAC), Mexico City, Mexico
5 shared publications Edmond J. Yunis
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
5 shared publicationsEsteban Arrieta-Bolaños
Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany
5 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by GRAPHIMEDIC SA DE CV in Revista Mexicana de Trasplantes
- Vol. 15 (S1) , 6-7
El de corazón humilde poseerá ciencia, verdad y servicio
- 1 January 2026
- Published by GRAPHIMEDIC SA DE CV in Revista Mexicana de Trasplantes
- Vol. 15 (S1) , 6-7
Open AccessEl de corazón humilde poseerá ciencia, verdad y servicio
- Open Access
- 4 July 2025
- Published by Instituto Mexicano del Seguro Social in Nefrología Mexicana
- Vol. 46 (2)
La enfermedad renal crónica
- 4 July 2025
- Published by Instituto Mexicano del Seguro Social in Nefrología Mexicana
- Vol. 46 (2)
Open AccessLa enfermedad renal crónica
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 25 (4) , 300-309
Understanding COVID-19-related Acute Renal Injury in Elderly Individuals: Preexisting Systemic Inflammation before COVID-19 (SIC)
In this study, we examined preexisting systemic inflammation before COVID-19 (SIC), as assessed through C-reactive protein (CRP) levels, to gain insights into the origins of acute kidney injury (AKI) in adults with comorbidities affected by COVID-19. Although aging is not categorized as a disease, it is characterized by chronic inflammation, and older individuals typically exhibit higher circulating levels of inflammatory molecules, particularly CRP, compared to younger individuals. Conversely, elevated CRP concentrations in older adults have been linked with the development of comorbidities. Simultaneously, these comorbidities contribute to the production of inflammatory molecules, including CRP. Consequently, older adults with comorbidities have higher CRP concentrations than their counterparts without comorbidities or those with fewer comorbidities. Given that CRP levels are correlated with the development and severity of AKI in non-COVID-19 patients, we hypothesized that individuals with greater SIC are more likely to develop AKI during SARS-CoV-2 infection than those with less SIC.
- 1 January 2025
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 25 (4) , 300-309
Understanding COVID-19-related Acute Renal Injury in Elderly Individuals: Preexisting Systemic Inflammation before COVID-19 (SIC)
In this study, we examined preexisting systemic inflammation before COVID-19 (SIC), as assessed through C-reactive protein (CRP) levels, to gain insights into the origins of acute kidney injury (AKI) in adults with comorbidities affected by COVID-19. Although aging is not categorized as a disease, it is characterized by chronic inflammation, and older individuals typically exhibit higher circulating levels of inflammatory molecules, particularly CRP, compared to younger individuals. Conversely, elevated CRP concentrations in older adults have been linked with the development of comorbidities. Simultaneously, these comorbidities contribute to the production of inflammatory molecules, including CRP. Consequently, older adults with comorbidities have higher CRP concentrations than their counterparts without comorbidities or those with fewer comorbidities. Given that CRP levels are correlated with the development and severity of AKI in non-COVID-19 patients, we hypothesized that individuals with greater SIC are more likely to develop AKI during SARS-CoV-2 infection than those with less SIC.
- Open Access
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e35841
Clinical impact using low-dose mycophenolate mofetil with tacrolimus on infectious, noninfectious complications and acute rejection, in renal transplant: A single hospital experience in Mexico
Evidence supporting a starting dose of 2 g/day of mycophenolate mofetil (MMF) in combination with tacrolimus (TAC) for renal transplantation (RT) is still limited, but maintaining a dose of vs 2 g of MMF. A prospective cohort study was performed with a 12-month follow-up of recipients of RT from living donors with low (1.5 g/day) or standard (2 g/day) doses of MMF. The association between adverse effects and complications and doses of MMF was examined using Cox proportional hazard models, and survival free of AR, infectious diseases, and noninfectious complications was evaluated using the Kaplan–Meier test. At the end of the follow-up, the incidence of infectious diseases was 52% versus 50% (P = .71) and AR was 5% versus 5% (P = .86), respectively. The survival rate free of gastrointestinal (GI) complications requiring medical attention was higher in the low-dose group than in the standard-dose dose (88% vs 45%, respectively; P < .001). The use of 1.5 g/day of MMF confers a reduction in GI complications without an increase in infectious diseases or the risk of AR.
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e35841
Open AccessClinical impact using low-dose mycophenolate mofetil with tacrolimus on infectious, noninfectious complications and acute rejection, in renal transplant: A single hospital experience in Mexico
Evidence supporting a starting dose of 2 g/day of mycophenolate mofetil (MMF) in combination with tacrolimus (TAC) for renal transplantation (RT) is still limited, but maintaining a dose of vs 2 g of MMF. A prospective cohort study was performed with a 12-month follow-up of recipients of RT from living donors with low (1.5 g/day) or standard (2 g/day) doses of MMF. The association between adverse effects and complications and doses of MMF was examined using Cox proportional hazard models, and survival free of AR, infectious diseases, and noninfectious complications was evaluated using the Kaplan–Meier test. At the end of the follow-up, the incidence of infectious diseases was 52% versus 50% (P = .71) and AR was 5% versus 5% (P = .86), respectively. The survival rate free of gastrointestinal (GI) complications requiring medical attention was higher in the low-dose group than in the standard-dose dose (88% vs 45%, respectively; P < .001). The use of 1.5 g/day of MMF confers a reduction in GI complications without an increase in infectious diseases or the risk of AR.
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 499-501
Genetic diversity of HLA system in two populations from Nayarit, Mexico: Tepic and rural Nayarit
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 499-501
Genetic diversity of HLA system in two populations from Nayarit, Mexico: Tepic and rural Nayarit
- Open Access
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 475-477
Genetic diversity of HLA system in four populations from Baja California, Mexico: Mexicali, La Paz, Tijuana and rural Baja California
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 475-477
Open AccessGenetic diversity of HLA system in four populations from Baja California, Mexico: Mexicali, La Paz, Tijuana and rural Baja California
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 510-512
Genetic diversity of HLA system in three populations from Guanajuato, Mexico: Guanajuato City, León and rural Guanajuato
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 510-512
Genetic diversity of HLA system in three populations from Guanajuato, Mexico: Guanajuato City, León and rural Guanajuato
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 482-484
Genetic diversity of HLA system in two populations from Sinaloa, Mexico: Culiacán and rural Sinaloa
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 482-484
Genetic diversity of HLA system in two populations from Sinaloa, Mexico: Culiacán and rural Sinaloa
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 506-509
Genetic diversity of HLA system in two populations from Michoacán, Mexico: Morelia and rural Michoacán
- 1 September 2020
- Published by Elsevier in Human Immunology
- Vol. 81 (9) , 506-509
Genetic diversity of HLA system in two populations from Michoacán, Mexico: Morelia and rural Michoacán